Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,378.0
16.9 (0.50%)

 

  • STI Straits Times Index
    3,378.0
    16.9 (0.50%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,658.2
    9.3 (0.56%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,765.4
    303.7 (1.07%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,924.2
    23.0 (0.79%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,467.0
    420.8 (2.00%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,456.5
    53.2 (0.83%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,094.4
    27.8 (1.35%)
    Index delayed 20 minutes
  • XAO XAO
    6,786.2
    50.8 (0.75%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 951.8M
  • Value: 1,059.6M
  • Rise: 198
  • Fall: 120
  • Unch: 520

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Libra0.052+0.025
QT Vascular0.006+0.002
Sino Grandness0.050+0.004
SunMoonFood^0.063+0.005
Koh Eco0.058+0.001
G Invacom^0.137+0.005
Genting Sing0.920-
Sen Yue0.038-
Golden Agri-Res0.300-
TEE Intl0.102+0.001

World Indices

World Indices
Name Last Change
Nasdaq 8,146.5 -60.8
HSI 28,765.4 +303.7
HSCEI 10,909.4 +124.9
Jakarta 6,456.5 +53.2
Nikkei 225 21,467.0 +420.8
SSE Comp 2,924.2 +23.0
Shanghai A 3,062.8 +24.1
Shanghai B 290.0 +1.3
ShenZhen A 1,631.7 +12.2
ShenZhen B 972.3 +3.6
Taiwan W 10,873.2 +73.9
PSE Comp 0.0
KOSPI 2,094.4 +27.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ACTINIUM PHARMACEUTICALS INC ACTINIUM PHARMACEUTICALS INC
Updated on 19 Jul 2019 (End of trading day)
Last (USD): 0.239 Change: +0.004 High: 0.250 Remarks: -
Change (%): +1.49 Low: 0.230
Open 0.238 Yesterday's Close 0.2352
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 519,586 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.30394 Trailing EPS (USD) e -0.35503 NAV (USD) b 0.1109
PE a - Trailing PE f - Price / NAV b 2.1524
Dividend (USD) d - Cash In Hand (USD) g 0.1432 Issued & Paid-up Shares c 161,996,000
Dividend Yield (%) d - Price / Cash In Hand g 1.667 Treasury Shares h -
Beta - 75 Daysi 0.716 R-Squared - 75 Days(%)i - Market Cap (M) 19.101
Beta - 500 Daysi -0.062 R-Squared - 500 Days (%)i 0.02 Enterprise Value (M) 7.645
Piotroski F Score 1 Exchange Code ATNM Par Value ( $ ) n.a.
52 Weeks Volatility (%) 90.01 Free Float (%) 99.0
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 24 Apr 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ACTINIUM PHARMACEUTICALS INC NYSE American 19.101 - - 2.1524 -
Industry Biotechnology NYSE American 77.051 - - 4.2460 -
Local Peer 22ND CENTURY GROUP INC NYSE American 198.327 - - 7.9686 -
Local Peer STANDARD DIVERSIFIED INC NYSE American 185.376 - - - -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 152.542 - - -8.0900 -
Local Peer PFENEX INC NYSE American 139.527 25.456 93.018 2.3396 -
Local Peer BIOTIME INC NYSE American 127.384 3.794 1.998 0.7233 -
Local Peer HEMISPHERX BIOPHARMA INC NYSE American 115.215 - - 11.1516 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 95.702 - - 5.7393 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 69.651 - - 14.4058 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 66.220 - - 7.0381 -
Local Peer IBIO INC NYSE American 66.830 - - 5.1613 -
Local Peer CEL-SCI CORP NYSE American 61.338 - - -11.5527 -
Local Peer INDIA GLOBALIZATION CAPITAL INC NYSE American 42.801 - - 5.8164 -
Other Local Peers ARMATA PHARMACEUTICALS INC (NYSE American), ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), NANOVIRICIDES INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American)
Global Peer AMGEN INC NASDAQ 108,806.483 12.962 13.474 10.0449 3.055
Global Peer GILEAD SCIENCES INC NASDAQ 82,702.262 15.161 14.036 3.7676 3.534
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CSL ASX 101,856.584 45.649 41.810 14.7785 1.014
Global Peer CELGENE CORP NASDAQ 63,614.452 15.723 13.407 7.7911 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 44,598.350 21.274 20.697 9.4422 -
Global Peer BIOGEN INC NASDAQ 44,841.634 10.121 9.609 3.2424 -
Global Peer ILLUMINA INC NASDAQ 43,100.400 52.180 50.647 10.8157 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,684.289 13.371 13.464 3.4606 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,087.830 349.072 65.052 2.7907 -
Other Global Peers AGILENT TECHNOLOGIES INC (NYSE), INCYTE CORPORATION (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), SEATTLE GENETICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), MODERNA INC (NASDAQ), 3SBIO (HKEx), Lonza (SGX), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), TILRAY INC (NASDAQ), FIBROGEN INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), LIGAND PHARMACEUTICAL INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), INSMED INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ANAPTYSBIO INC (NASDAQ), VERACYTE INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), OPKO HEALTH INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), INTREXON CORP (NASDAQ), EDITAS MEDICINE INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), CORTEXYME INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), RADIUS HEALTH INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), HAOHAI BIOTEC (HKEx), NGM BIOPHARMACEUTICALS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), FRONTAGE (HKEx), KURA ONCOLOGY INC (NASDAQ), RETROPHIN INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), VIVA BIOTECH (HKEx), ALDER BIOPHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ASCLETIS-B (HKEx), ARVINAS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), OMEROS CORP (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), VANDA PHARMACE INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), PERSONALIS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), SYNTHORX INC (NASDAQ), ESSEX BIO-TECH (HKEx), KODIAK SCIENCES INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), GLYCOMIMETICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NEXT SCIENCE LTD (ASX), AURINIA PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), TRANSLATE BIO INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), PROTHENA CORP PLC (NASDAQ), NEXTCURE INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), RESTORBIO INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERUS B V (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), IMMUNOGEN INC (NASDAQ), AGENUS INC (NASDAQ), KADMON HLDGS INC (NYSE), ACHILLION PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), TELIX PHARMACEUTIC (ASX), SYNDAX PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), GERON CORP (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), RECRO PHARMA INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), CHIASMA INC (NASDAQ), AFFIMED N V (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CHIMERIX INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), AXOVANT GENE THERAPIES LTD (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), ARDELYX INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), IMV INC (NASDAQ), BBI LIFE SCI (HKEx), TOCAGEN INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SESEN BIO INC (NASDAQ), NANTKWEST INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ADURO BIOTECH INC (NASDAQ), VERASTEM INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), UNI-BIO GROUP (HKEx), CYNATA THERAPEUTICS LTD (ASX), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), INMUNE BIO INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), SUNESIS PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), EQUILLIUM INC (NASDAQ), TREVENA INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SAVARA INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), PORT (SET), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VERMILLION INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), ORGENESIS INC (NASDAQ), CURIS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), COHBAR INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ARAVIVE INC (NASDAQ), CT ENTERPRISE (HKEx), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), REGENT PACIFIC (HKEx), IMMUTEP LTD (ASX), OPIANT PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), PHYLOGICA LIMITED (ASX), ORTHOCELL LIMITED (ASX), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ZAFGEN INC (NASDAQ), IMUGENE LIMITED (ASX), SEELOS THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), EVOGENE LTD (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), ZELDA THERAPEUTICS LTD (ASX), CONTRAFECT CORP (NASDAQ), RHINOMED LIMITED (ASX), BIOTRON (ASX), SENESTECH INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), EXTRAWELL PHAR (HKEx), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), ONCOLYTICS BIOTECH INC (NASDAQ), MEMPHASYS LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), HEAT BIOLOGICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SOLIGENIX INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ADALTA LTD (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), BIOCEPT INC (NASDAQ), HISTOGENICS CORP (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), PATRYS LIMITED (ASX), PRECIPIO INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), VICAL INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), IMMURON LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), BIONOMICS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), OHR PHARMACEUTICAL INC (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ATYR PHARMA INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), NOVELION THERAPEUTICS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), GENETIC TECHNOLOGIES (ASX), REGENEUS LTD (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), CELLMID LIMITED (ASX), TROVAGENE INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), Suntar Eco-City^ (SGX), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), ADVAXIS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), BENITEC BIOPHARMA LTD (ASX), NEURALSTEM INC (NASDAQ), BIOXYNE LIMITED (ASX), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), QT Vascular (SGX), ACTINOGEN MEDICAL LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), MGRC (Bursa), MEGASUN (Bursa), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), OPGEN INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), CYTORI THERAPEUTICS INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), XENETIC BIOSCIENCES INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NOVITA HEALTHCARE LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), MEDIBIO LIMITED (ASX), BPH ENERGY LIMITED (ASX), SINOVAC BIOTECH (NASDAQ), ALCHEMIA LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.007
+2.89 %
10 Days --0.009
-3.75 %
20 Days --0.026
-9.92 %
Medium Term Return 3 Months --0.071
-23.00 %
6 Months --0.246
-50.78 %
1 Year --0.546
-69.59 %
Long Term Return 2 Years --0.781
-76.60 %
3 Years --1.531
-86.51 %
5 Years --6.751
-96.59 %
Annualised Return Annualised --
-49.11 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.230 - 0.865 Change From 1 Year Low +0.009 % Change From 1 Year Low (%) +3.78
Change From 1 Year High -0.626 % Change From 1 Year High (%) -72.41
2 Years Range 0.230 - 1.040 Change From 2 Years Low +0.009 % Change From 2 Years Low (%) +3.78
Change From 2 Years High -0.801 % Change From 2 Years High (%) -77.05
5 Years Range 0.230 - 8.120 Change From 5 Years Low +0.009 % Change From 5 Years Low (%) +3.78
Change From 5 Years High -7.881 % Change From 5 Years High (%) -97.06
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Jul 2019 0.238 0.250 0.230 0.239 519,586 -
18 Jul 2019 0.235 0.236 0.230 0.235 356,426 -
17 Jul 2019 0.238 0.238 0.230 0.230 303,706 -
16 Jul 2019 0.240 0.240 0.230 0.230 521,386 -
15 Jul 2019 0.240 0.240 0.230 0.240 464,475 -
12 Jul 2019 0.237 0.240 0.232 0.232 422,624 -
11 Jul 2019 0.249 0.249 0.235 0.237 459,800 -
10 Jul 2019 0.250 0.250 0.237 0.240 425,938 -
09 Jul 2019 0.245 0.250 0.235 0.245 511,496 -
08 Jul 2019 0.255 0.265 0.239 0.239 1,197,288 -
05 Jul 2019 0.240 0.249 0.240 0.248 364,232 -
03 Jul 2019 0.230 0.247 0.230 0.240 389,515 -
02 Jul 2019 0.247 0.250 0.240 0.247 637,014 -
01 Jul 2019 0.255 0.259 0.245 0.245 362,205 -
28 Jun 2019 0.250 0.260 0.246 0.246 826,574 -
27 Jun 2019 0.250 0.255 0.245 0.247 306,306 -
26 Jun 2019 0.263 0.263 0.240 0.250 512,774 -
25 Jun 2019 0.275 0.275 0.240 0.256 922,070 -
24 Jun 2019 0.270 0.270 0.253 0.260 420,502 -
21 Jun 2019 0.262 0.275 0.251 0.265 509,625 -
20 Jun 2019 0.265 0.266 0.250 0.264 325,176 -
19 Jun 2019 0.256 0.269 0.252 0.262 401,979 -
Summary
Current 2 Weeks
(08 Jul 2019 to 19 Jul 2019)
0.255 0.265 0.230 0.239 5,182,725 -
Previous 2 Weeks
(21 Jun 2019 to 05 Jul 2019)
0.262 0.275 0.230 0.248 5,250,817 -
4 Weeks from
(23 May 2019 to 20 Jun 2019)
0.288 0.297 0.230 0.264 32,984,773 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.